Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

IRLAB Therapeutics

MCap

SEK653m

Last close

SEK14.10

▲ 1.50 (11.90%)

VolitionRx

MCap

USD51m

Last close

USD0.60

▲ 0.05 (9.82%)

Portobello SpA

MCap

EUR12m

Last close

EUR2.38

▲ 0.20 (9.17%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

EVT801, Kazia’s second programme, and capital markets

EVT801, Kazia’s second programme, and capital markets

Kazia Therapeutics — 9 videos in collection

More on this equity

In the third part of our Edison TV series on Kazia Therapeutics (KZIA), John Friend, CMO, and James Garner, CEO, discuss the company’s second pipeline asset, EVT801. EVT801 is a small molecule inhibitor of VEGFR3, which preclinical data have shown to be active against a broad range of tumour types and provided compelling evidence of synergy with immunoncology agents.

Additionally, Karen Krumeich, CFO, discusses Kazia’s focus on increasing awareness of the company in the US capital markets. 2022 is a data-rich year for Kazia and this episode concludes with an overview of the anticipated milestones and catalysts.

< Previous

Next >

You may also be interested in these:

Healthcare

29.06.22

Kazia Therapeutics webinar - Combating childhood brain cancer

Healthcare

10.05.22

Paxalisib: Beyond glioblastoma and commercial opportunity

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free